Yahoo India Web Search

Search results

    • Rs 85 crore

      • Pathology company Dr Lal PathLabs Limited on May 10 reported 52 percent jump in consolidated net profit at Rs 85 crore for the quarter ended 31 March, 2024. The company had reported a net profit of Rs 56 crore in the year-ago period. Revenue from operations increased 11 percent to Rs 545 crore from Rs 491 crore in the said quarter.
  1. People also ask

  2. Results for Quarter ended September 30, 2021. Press Release. Press Release Q2 FY 2022. Earnings Presentation. Earning Presentation Q2 FY 2022. Unaudited Financial Results. Unaudited Financial Result-Q2 FY 2022.

  3. Get Dr Lal PathLabs latest Quarterly Results, Financial Statements and Dr Lal PathLabs detailed profit and loss accounts.

  4. Dr Lal Pathlabs Quarterly results. BSE: 539524 | NSE: LALPATHLABEQ | IND: Diagnostics | ISIN code: INE600L01024 | SECT: Hospitals & Allied Services. The Quarterly Results page of Dr. Lal Pathlabs Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results. TOTAL INCOME. 13.78 % Rs 563.30Cr.

  5. Quarterly & Annual Financial Results of Dr Lal Pathlabs Ltd Check latest quarterly results and compare financial performance over past years. Get latest Standalone, Consolidated and Segment wise financial results.

  6. Jul 28, 2022 · Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

  7. Dr Lal PathLabs Limited records revenue of Rs 491 Cr in Q4 FY 2022-23. New Delhi, India, May 11, 2023 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2023. .

  8. May 10, 2024 · Pathology company Dr Lal PathLabs Limited on May 10 reported 52 percent jump in consolidated net profit at Rs 85 crore for the quarter ended 31 March, 2024.